GlassScriptPhysician profile
Melissa Jamison
NPI 1164680039
$4,317.83
in general payments reported to CMS, 2019-2025
23 companies · $1,066 in 2025
The $1,066 reported for 2025 was more than what 84% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $485 · 2022: $808 · 2023: $849 · 2024: $1,109 · 2025: $1,066.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,011 · Education: $13.32.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,011.00 |
| Education | $13.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,897.21 | 2021-2025 | |
| Janssen Biotech, INC. | $564.30 | 2021-2025 | Stelara, Tremfya |
| Madrigal Pharmaceuticals | $520.87 | 2024-2025 | Rezdiffra, Resmetirom |
| Takeda Pharmaceuticals U.S.A., INC. | $369.38 | 2022-2025 | Eohilia, Entyvio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $180.10 | 2021-2025 | Xifaxan |
| Genzyme Corporation | $153.90 | 2022-2025 | |
| Amgen INC. | $93.95 | 2021-2023 | Amjevita, Avsola |
| Intercept Pharmaceuticals, INC. | $88.70 | 2023-2025 | Ocaliva |
| Celgene Corporation | $55.95 | 2022-2023 | Zeposia |
| Phathom Pharmaceuticals, INC. | $53.85 | 2024-2025 | Voquezna |
| Redhill Biopharma INC. | $49.90 | 2021-2022 | |
| Medtronic, INC. | $45.88 | 2025 | Interstim |
| Ardelyx, INC. | $41.67 | 2022-2024 | Ibsrela |
| Celltrion USA INC. | $35.95 | 2024-2025 | Vegzelma, Zymfentra |
| Mindray Ds USA, INC. | $28.57 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $22.99 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $22.17 | 2022 | |
| Daiichi Sankyo INC. | $18.29 | 2021 | |
| Aimmune Therapeutics, INC. | $17.69 | 2024 | |
| Avanos Medical | $16.94 | 2021 | |
| Ironwood Pharmaceuticals, INC | $14.64 | 2023 | Linzess |
| Ferring Pharmaceuticals INC. | $13.54 | 2024 | Rebyota |
| Nestle Healthcare Nutrition INC. | $11.39 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Jamison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.